-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor Epidemic cerebrospinal meningitis (meningitis for short) is an acute and severe infectious disease caused by Neisseria meningitidis.
It is spread through the respiratory or throat secretions of patients and carriers, mainly by A , B, C, X, W135 or Y serogroups
.
After Neisseria meningitidis enters the blood circulation, it will form a purulent inflammation, the onset is uncertain, and it is difficult to diagnose
.
According to the World Health Organization (WHO), if the disease is not diagnosed in time, the mortality rate can reach more than 50%, and it may even be life-threatening within 24 hours.
Even patients who survive after rescue may have intelligence Severe effects such as dullness, impaired hearing and even amputation
.
The disease has the highest incidence in children under 5 years of age, especially infants and young children aged 6 months to 2 years
.
Image source: 123RF According to the Public Health Data Center, the meningococcal meningitis database shows that 1 in 4 children with meningitis under the age of 1 die
.
Recently, the China National Medical Products Administration (NMPA) announced that the ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier, trade name: Manhaixin) has been approved
.
Screenshot source: Public information on NMPA’s official website shows that this quadrivalent meningococcal conjugate vaccine, Manhaixin, independently developed by a Chinese company, has been included in the priority review by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, and is intended to be used for prevention Meningococcal meningitis caused by group A, group C, group Y and group W135 meningococcus
.
It fills the gap in the field of innovative vaccines for the prevention and treatment of acute infectious meningitis in young children (under 2 years old) in China
.
Manhaixin covalently binds four common pathogenic meningococcal serogroups A, C, W135 and Y to the carrier protein CRM197 respectively.
It is the first conjugate vaccine covering the most serogroups in China, making the vaccine protective Sex is wider
.
Image source: 123RF As Professor Yang Yonghong, former vice president of Beijing Children's Hospital and expert in children's respiratory and infectious diseases, said: "The development and active application of a meningococcal vaccine with a wider serogroup coverage will be more helpful for meningococcal disease.
It is worth mentioning that
in
the preparation process of this product, no preservative ingredients such as phenol are added, and no animal-derived ingredients are used, making the vaccine safer, more environmentally friendly, and meeting the needs of special populations
.
In addition, the clinical trial results of Mannhaixin showed that after using 3 immunization programs for 3 months old, 2 immunization programs for 6-23 months old, and 1 immunization program for 2-6 year old healthy children, All showed good safety and immunogenicity
.
It is hoped that the quadrivalent meningococcal conjugate vaccine will come to patients as soon as possible and provide a new choice for children to prevent epidemic meningitis! Recommended reading The treatment of common pneumonia, the approval of new antibiotics for the marketing of fungal infectious diseases with a very high fatality rate, ushered in a new oral drug and another new drug approved in China, reducing the recurrence rate by more than 50% every year! The first-line treatment of non-small cell lung cancer can be done at home, and the new PD-L1 monoclonal antibody has been approved for marketing.
Another new cancer drug has been approved in China! This refractory tumor has a new choice of reference materials [1] The first domestic ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier) is officially approved.
Retrieved Jan 6, 2022, from https://mp.
weixin.
qq.
com/s?src=11×tamp=1641806732&ver=3550&signature=Zlc5wQhtL*0u88wGqRocSNJPGor8ine9SDKClGg8RNvXdKbKFUMQVv0zmEwG0RaMBbZEQp1YpdVKXn5dO4acksBCzbH00ebonxwSdDf1Srx6ViGC4P7DUrEznPBDhsHG&new=1 Disclaimer: WuXi content teams to focus global progress in biomedical health research presentation
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
It is spread through the respiratory or throat secretions of patients and carriers, mainly by A , B, C, X, W135 or Y serogroups
.
After Neisseria meningitidis enters the blood circulation, it will form a purulent inflammation, the onset is uncertain, and it is difficult to diagnose
.
According to the World Health Organization (WHO), if the disease is not diagnosed in time, the mortality rate can reach more than 50%, and it may even be life-threatening within 24 hours.
Even patients who survive after rescue may have intelligence Severe effects such as dullness, impaired hearing and even amputation
.
The disease has the highest incidence in children under 5 years of age, especially infants and young children aged 6 months to 2 years
.
Image source: 123RF According to the Public Health Data Center, the meningococcal meningitis database shows that 1 in 4 children with meningitis under the age of 1 die
.
Recently, the China National Medical Products Administration (NMPA) announced that the ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier, trade name: Manhaixin) has been approved
.
Screenshot source: Public information on NMPA’s official website shows that this quadrivalent meningococcal conjugate vaccine, Manhaixin, independently developed by a Chinese company, has been included in the priority review by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, and is intended to be used for prevention Meningococcal meningitis caused by group A, group C, group Y and group W135 meningococcus
.
It fills the gap in the field of innovative vaccines for the prevention and treatment of acute infectious meningitis in young children (under 2 years old) in China
.
Manhaixin covalently binds four common pathogenic meningococcal serogroups A, C, W135 and Y to the carrier protein CRM197 respectively.
It is the first conjugate vaccine covering the most serogroups in China, making the vaccine protective Sex is wider
.
Image source: 123RF As Professor Yang Yonghong, former vice president of Beijing Children's Hospital and expert in children's respiratory and infectious diseases, said: "The development and active application of a meningococcal vaccine with a wider serogroup coverage will be more helpful for meningococcal disease.
It is worth mentioning that
in
the preparation process of this product, no preservative ingredients such as phenol are added, and no animal-derived ingredients are used, making the vaccine safer, more environmentally friendly, and meeting the needs of special populations
.
In addition, the clinical trial results of Mannhaixin showed that after using 3 immunization programs for 3 months old, 2 immunization programs for 6-23 months old, and 1 immunization program for 2-6 year old healthy children, All showed good safety and immunogenicity
.
It is hoped that the quadrivalent meningococcal conjugate vaccine will come to patients as soon as possible and provide a new choice for children to prevent epidemic meningitis! Recommended reading The treatment of common pneumonia, the approval of new antibiotics for the marketing of fungal infectious diseases with a very high fatality rate, ushered in a new oral drug and another new drug approved in China, reducing the recurrence rate by more than 50% every year! The first-line treatment of non-small cell lung cancer can be done at home, and the new PD-L1 monoclonal antibody has been approved for marketing.
Another new cancer drug has been approved in China! This refractory tumor has a new choice of reference materials [1] The first domestic ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier) is officially approved.
Retrieved Jan 6, 2022, from https://mp.
weixin.
qq.
com/s?src=11×tamp=1641806732&ver=3550&signature=Zlc5wQhtL*0u88wGqRocSNJPGor8ine9SDKClGg8RNvXdKbKFUMQVv0zmEwG0RaMBbZEQp1YpdVKXn5dO4acksBCzbH00ebonxwSdDf1Srx6ViGC4P7DUrEznPBDhsHG&new=1 Disclaimer: WuXi content teams to focus global progress in biomedical health research presentation
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
